Foundation Fighting Blindness

Foundation Fighting Blindness

Early clinical trial results show vision gains in patients with BEST1-related disease

OCT 2, 20264 MIN

Description

Opus Genetics has shared encouraging early results from its ongoing Phase 1/2 clinical trial for OPGx-BEST1, a potential one-time gene therapy for people with BEST1-related retinal disease. All five patients enrolled in the clinical trial had clinically meaningful improvement in visual function, according to Opus Genetics. The greatest functional improvements were observed in participants with less advanced disease.